Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126793
Filing Date
2024-11-14
Accepted
2024-11-14 09:30:30
Documents
40
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20240930.htm   iXBRL 10-Q 1382281
2 EX-31.1 tcrt-ex31_1.htm EX-31.1 13631
3 EX-32.1 tcrt-ex32_1.htm EX-32.1 7299
  Complete submission text file 0000950170-24-126793.txt   4231878

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20240930.xsd EX-101.SCH 610502
42 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20240930_htm.xml XML 446312
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 241457791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)